Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||GSK2801 + HY-16462|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GSK2801||GSK 2801|GSK-2801||GSK2801 is a bromodomain inhibitor that selectively inhibits BAZ2A/B and BRD9, which has potential antitumor activity (PMID: 31000582).|
|HY-16462||HY16462|HY 16462||CDK9 Inhibitor 19||HY-16462 is a CDK9 inhibitor, which has potential antitumor activity (PMID: 31000582).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||no benefit||GSK2801 + HY-16462||Preclinical - Cell culture||Actionable||In a preclinical study, GSK2801 and HY-16462 combination treatment did not synergistically inhibit growth of a triple-negative breast cancer cell line in culture (PMID: 31000582).||31000582|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|